Loconte, Manlio

Loconte, Manlio was paid $235K by Medicaid between Jan 2018 and Mar 2023, across 3 billing codes. Its largest line is 80307, Drug test(s), presumptive, any number of drug classes; immunoassay — 38% of everything it billed.

33Billing provider infoLOCONTE, MANLIO
BOSTON, MA 02111

33aNPI1114984820assigned 04/27/2006

33bProvider typeAnatomic Pathology Physician

28Total paid$235K

24GClaims4,461

24DCodes billed3

24AFirst – last monthJan 2018 – Mar 2023

Compared with peers

Next to other Anatomic Pathology Physician providers in Massachusetts

Rank by total paid#4 of 68

Median peer was paid$7K

This provider vs. median32×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	726	$38K
2019	290	$15K
2020	859	$46K
2021	1,380	$73K
2022	1,017	$54K
2023	189	$10K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	38%	1,860	956	$88K
99213	Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity	36%	1,571	947	$85K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	26%	1,030	550	$62K

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.